The Latest Breaking News from Albert Bourla

Pfizer CEO certain that Trump’s administration ‘will be very, very prudent with everything they try to do’

For savvy investors, Pfizer could be an undervalued stock to buy here.

This dividend stock is now on the radar of activist investors, with Starboard eyeing a possible management shakeup.

The drugmaker has shed nearly $180 billion in market cap after struggling to chart a new course as the COVID-19 pandemic waned.

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

A Belgian court on Friday heard a lawsuit accusing European Commission chief Ursula von der Leyen of secretly negotiating Covid vaccine purchases via text message and arguing she should be barred from a second term.

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

Pfizer issued a disappointing 2024 forecast Wednesday, denting shares as the company navigates a profound plunge in sales tied to the Covid-19 pandemic.

Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles.